Related Experiment Videos
[Use of beta-adrenoreceptor antagonists in treatment of patients with chronic heart failure]
Insights
Beta-blockers, like carvedilol, show promise in treating chronic heart failure (CHF) by protecting the heart muscle and reducing cell death. Ongoing research is evaluating their effectiveness and comparing different beta-blockers for CHF management.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Chronic heart failure (CHF) affects 1-10% of the global population.
- Current treatments improving survival, such as ACE inhibitors and nitrates with hydralazine, act on neurohormonal factors.
- Beta-blockers are gaining attention for their potential to halt CHF progression.
Purpose:
- To explore the mechanisms and benefits of beta-blockers in managing chronic heart failure.
- To highlight the role of carvedilol, a multi-acting beta-blocker with antioxidant properties, in improving CHF outcomes.
Summary:
- Beta-blockers offer protective effects on the myocardium and inhibit apoptosis (programmed cell death), which is heightened in CHF.
- Carvedilol has demonstrated improvements in clinical status and reductions in all-cause mortality in CHF patients.
- Extensive clinical trials are currently underway to assess various beta-blockers and their comparative efficacy in CHF.
Impact:
- Beta-blockers represent a significant therapeutic advancement for chronic heart failure.
- Understanding their mechanisms can lead to improved patient management and reduced mortality.
- Further research will refine the use of beta-blockers in CHF treatment protocols.
Abstract:
Chronic heart failure (CHF) is present in 1-10% of the whole population. From the drugs used in CHF so far only angiotensin converting enzyme inhibitors and nitrate with hydralazine improved the survival which was caused by beneficial influence of these drugs on neurohormonal factors. There is growing interest in beta-blockers which are believed to stop the progress of CHF. Although the first attempts of using beta-blockers in the treatment of CHF took place in 70-ties, only recent years brought better understanding of mechanisms of their action. The beneficial effect of beta-blockers in CHF is related to their protective influence on myocardium and to hampering of apoptosis--programmed cell death--the phenomenon which is exaggerated in CHF. The investigations carried out in last years proved that carvedilol which is beta 1-, beta 2- and alpha 1-blocker and has antioxidant properties improved clinical status and reduced mortality in the cohorts of patients with all-cause CHF. At present great trials estimating various beta-blockers and comparing these drug among themselves are being conducted.